Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A FPBCC Clinical Trials Network Phase I Study

被引：0
|
作者：
Umakanthan, J. Manikkam [1 ]
Marr, A. [1 ]
Ernani, V. [1 ]
Kessinger, M. [1 ]
Smith, L. [2 ]
Tijerina, J. [1 ]
Radniecki, S. [1 ]
Kosmacek, E. [1 ]
Ketcham, M. [1 ]
Ganti, A. K. [3 ,4 ]
机构：
[1] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Div Hematol & Oncol, Omaha, NE USA
[2] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE USA
[3] Va Nebraska Western Iowa Hlth Care Syst, Div Hematol & Oncol, Omaha, NE USA
[4] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
small cell lung cancer; topotecan; Doxorubicin;
D O I：
10.1016/j.jtho.2017.09.1406
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.15-013
引用
收藏
页码：S2188 / S2188
页数：1
相关论文
共 50 条
  • [1] Late phase II trials of topotecan (T) for relapsed small cell lung cancer (SCLC)
    Nishiwaki, Y
    Negoro, S
    Watanabe, K
    Fukuoka, M
    Niitani, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [2] A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC).
    Leach, J. W.
    Swenson, K.
    Anderson, E.
    Menge, M. R.
    Tsai, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC)
    Kontopodis, E.
    Vamvakas, L.
    Kalbakis, K.
    Vardakis, N. K.
    Sfakiotaki, G.
    Georgoulias, V.
    Agelaki, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC)
    Ardizzoni, A
    Hansen, HH
    Dombernowsky, P
    Kaplan, S
    Postmus, PE
    Gamucci, T
    Schaefer, B
    Wanders, J
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 84 - 84
  • [5] Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
    Heist, Rebecca Suk
    Fain, Jerry
    Chinnasami, Bernard
    Khan, Waseem
    Molina, Julian R.
    Sequist, Lecia V.
    Temel, Jennifer S.
    Fidias, Panos
    Brainerd, Valari
    Leopold, Lance
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1637 - 1643
  • [6] Phase I study of weekly topotecan (T) in recurrent small cell lung cancer (SCLC)
    Groteluschen, D
    Traynor, A
    Schiller, J
    Dubey, S
    Hoang, T
    Kim, K
    Hansen, R
    Kwong, R
    Hammes, L
    Liverseed, K
    LUNG CANCER, 2005, 49 : S320 - S320
  • [7] Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/Refractory Small Cell Lung Cancer
    Chawla, Shanta
    Wieland, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S742 - S742
  • [8] Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC)
    Han, J.
    Lim, K. Y.
    Kim, H. Y.
    Han, J. H.
    Oh, S. H.
    Yun, T.
    Kim, H. T.
    Lee, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer (SCLC)
    Pietanza, M. C.
    Sima, C. S.
    Polley, M. R.
    Sumner, D. K.
    Travis, V.
    Heguy, A.
    Ginsberg, M. S.
    Holodny, A.
    Kris, M. G.
    Krug, L. M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S507 - S507
  • [10] A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
    S. Agelaki
    E. Kontopodis
    A. Kotsakis
    V. Chandrinos
    I. Bompolaki
    Ζ. Zafeiriou
    E. Papadimitraki
    D. Stoltidis
    K. Kalbakis
    V. Georgoulias
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 45 - 51
12345